Hostname: page-component-59f8fd8595-gl4p7 Total loading time: 0 Render date: 2023-03-21T15:34:38.179Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true
  • English

Botulinum Toxin Type A and Acute Drug Costs in Migraine with Triptan Overuse

Published online by Cambridge University Press:  02 December 2014

Suzanne N. Christie ,
Rose Giammarco ,
Marek Gawel ,
Gordon Mackie ,
Jonathan Gladstone  and
Werner J. Becker
Suzanne N. Christie
Affiliation:
Department of Neurology, University of Ottawa, Ottawa
Rose Giammarco
Affiliation:
Department of Neurology, McMaster University, Hamilton
Marek Gawel
Affiliation:
Department of Neurology, University of Toronto, Toronto
Gordon Mackie
Affiliation:
Department of Neurology, Richmond Hospital, Richmond, British Columbia
Jonathan Gladstone
Affiliation:
Gladstone Headache Clinic, Toronto, Ontario
Werner J. Becker*
Affiliation:
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
*
Division of Neurology, Foothills Hospital, 1403 29th St NW, Calgary, Alberta, T2N 2T9, Canada.
Rights & Permissions[Opens in a new window]

Abstract

HTML view is not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Patients with chronic migraine and medication overuse are significant consumers of health care resources.

Objective:

To determine whether botulinum toxin type A prophylaxis reduces the cost of acute migraine medications in patients with chronic migraine and triptan overuse.

Methods:

In this multicenter, open-label study, patients with chronic migraine (≥15 headache days/month) who were triptan overusers (triptan intake ≥10 days/month for ≥3 months) received botulinum toxin type A (95-130 U) at baseline and month three. Headache (HA) frequency and medication use were assessed with patient diaries, and headache-related disability by means of the MIDAS and Headache Impact Test-6 questionnaires.

Results:

Of 53 patients enrolled (mean age ± standard deviation, 46.5 years ± 8.4; 47 [88.7%] females), 48 (90.6%) completed the study at month six. Based on headache diaries, significant (P≤0.0002) decreases from baseline were observed for days per month with headache/migraine, days with any acute headache medication use, days with triptan use, and triptan doses taken per month. A significant (P<0.0001) increase from baseline in headache-free days per month was also observed. Prescription medication costs for acute headache medications decreased significantly, including significant reductions in triptan costs (mean reduction of -C$106.32 ± 122.87/month during botulinum toxin type A prophylaxis; P<0.0001). At baseline, 78% of patients had severe disability (MIDAS score) and 86.8% had severe impact due to headache (HIT-6 scores); at month six, this decreased to 60% and 68%, respectively.

Conclusions:

Botulinum toxin type A prophylactic therapy markedly decreased costs related to acute headache medication use in patients with chronic migraine and triptan overuse.

Résumé:

RÉSUMÉ:Contexte:

Les patients qui souffrent de migraine chronique et qui surutilisent leur médication sont des consommateurs importants de soins de santé.

Objectif:

Le but de l’étude était de déterminer si la prophylaxie par la toxine botulique de type A (BoNTA) diminue le coüt de la médication utilisée pour traiter la migraine aigue chez les patients qui souffrent de migraine chronique et qui surutilisent les triptans.

Méthodes:

Au cours de cette étude ouverte, multi¬centres, les patients atteints de migraine chronique (> 15 jours de céphalée par mois) qui surutilisaient des triptans (prise de triptans > 10 jours par mois pendant > 3 mois) ont recu de la toxine botulique de type A (95-130 U) au début de l’étude et 3 mois plus tard. La frequence des céphalées et l’utilisation de la médication ont été évaluées au moyen de carnets de migraine et l’invalidité due à la céphalée au moyen des tests de migraine MIDAS et HIT-6.

Résultats:

Quarante-huit (90,6%) des 53 patients admis dans l’étude ont complété cette étude de 6 mois (àge moyen 46,5 ± 8,4 ans ; 47 femmes, soit 88,7%). Selon les carnets de migraine remplis par les patients, une diminution significative (p < 0,0002) du nombre de jours par mois où la céphalée/la migraine était présente, où une médication contre la céphalée aigue a été utilisée et où un triptan a été utilisé, ainsi qu’une diminution des doses de triptan ont été observées par rapport au début de l’étude. Une augmentation significative (p < 0,0001) du nombre de jours par mois sans céphalée a également été observée. Les coüts des médicaments sous prescription pour les médicaments contre la céphalée aigue ont diminué significativement, dont une diminution significative des coüts reliés à l’utilisation des triptans (diminution moyenne de -106,32 ± 122,87 $CA/mois pendant la prophylaxie par BoNTA ; p < 0,0001). Au début de l’étude, l’invalidité était sévère chez 78% des patients (score MIDAS) et 86,8% avaient un impact sévère dü à la céphalée (score HIT-6) ; après 6 mois, les pourcentages avaient diminué à 60% et 68% respectivement.

Conclusions:

La prophylaxie par la toxine botulique de type A diminue de facon appréciable les coüts associés à l’utilisation de la médication contre la céphalée aigue chez les patients atteints de migraine chronique qui surutilisent les triptans.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 37 , Issue 5 , September 2010 , pp. 588 - 594
Copyright
Copyright © The Canadian Journal of Neurological 2010

References

1. Wilkinson, SM, Becker, WJ, Heine, JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001 Mar;41(3):303–9.CrossRefGoogle ScholarPubMed
2. Bahra, A, Walsh, M, Menon, S, Goadsby, PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003 Mar;43(3):179–90.CrossRefGoogle ScholarPubMed
3. Limmroth, V, Katsarava, Z, Fritsche, G, Przywara, S, Diener, HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002 Oct 8;59(7): 1011–4.CrossRefGoogle ScholarPubMed
4. Katsarava, Z, Fritsche, G, Muessig, M, Diener, HC, Limmroth, V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001 Nov 13;57 (9):1694–8.CrossRefGoogle ScholarPubMed
5. Andrasik, F, Grazzi, L, Usai, S, D’Amico, D, Kass, S, Bussone, G. Disability in chronic migraine with medication overuse: treatment effects at 3 years. Headache. 2007;47:1277-81CrossRefGoogle ScholarPubMed
6. Zeeberg, P, Olesen, J, Jensen, R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology. 2006 Jun 27;66(12):1894–8.CrossRefGoogle ScholarPubMed
7. Diener, HC, Dodick, DW, Goadsby, PJ, Bigal, ME, Bussone, G, Silberstein, SD, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009 Oct;29(10): 1021–7.CrossRefGoogle ScholarPubMed
8. Diener, HC, Bussone, G, Van Oene, JC, Lahaye, M, Schwalen, S, Goadsby, PJ; TOPMAT-MIG-201 (TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007 Jul;27(7):814–23.CrossRefGoogle Scholar
9. Silberstein, SD, Stark, SR, Lucas, SM, Christie, SN, Degryse, RE, Turkel, CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80(9): 1126–37.CrossRefGoogle ScholarPubMed
10. Dodick, DW, Mauskop, A, Elkind, AH, DeGryse, R, Brin, MF, Silberstein, SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005;45(4):315–24.CrossRefGoogle Scholar
11. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia. 2004;24 Suppl 1:1–160.Google Scholar
12. Blumenfeld, AM, Binder, W, Silberstein, SD, Blitzer, A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache. 2003;43(8):884–91.CrossRefGoogle ScholarPubMed
13. Silberstein, SD, Winner, PK, Chmiel, JJ. Migraine preventive medication reduces resource utilization. Headache. 2003;43(3): 171–8.CrossRefGoogle ScholarPubMed
14. Etemad, LR, Yang, W, Globe, D, Barlev, A, Johnson, KA. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):137–44.Google Scholar
15. Dodick, D, Silberstein, S. Central sensitization theory of migraine: clinical implications. Headache. 2006;46 Suppl 4:S182–S91.CrossRefGoogle ScholarPubMed
16. Durham, PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46 Suppl 1:S3–8.CrossRefGoogle ScholarPubMed
17. Goadsby, PJ. Migraine pathophysiology. Headache. 2005;45 Suppl 1:S14–S24.CrossRefGoogle ScholarPubMed
18. Aoki, KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(Suppl 1):9–15.CrossRefGoogle ScholarPubMed
19. Aoki, KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26(5): 785–93.CrossRefGoogle ScholarPubMed